Yellow Fever (Acute Fever)

What is Yellow Fever (Acute Fever)?

Yellow fever is a viral hemorrhagic disease transmitted primarily by the bite of infected Aedes or Haemagogus mosquitoes. The illness is named for the yellow‑tinted jaundice that can develop in severe cases. It typically begins with an abrupt onset of high fever (often > 39 °C/102 °F) and flu‑like symptoms, earning the lay description “acute fever.” While many infections are mild, a proportion progress to a toxic phase marked by liver failure, bleeding, and a high case‑fatality rate if not treated promptly.

Yellow fever is endemic in parts of sub‑Saharan Africa and tropical South America. Travelers to these regions who are not vaccinated are at greatest risk. The disease is a major public‑health concern because it can cause outbreaks, especially in areas with low immunization coverage.

Common Causes

Although the term “yellow fever” specifically refers to infection with the Yellow fever virus (YFV), an acute febrile illness can result from several other infectious and non‑infectious conditions that mimic its presentation. The list below includes the most common etiologies of an acute febrile syndrome in endemic regions and in travelers.

• Yellow fever virus infection – the classic cause.
• Dengue fever – another mosquito‑borne flavivirus.
• Chikungunya virus – arthritic fever transmitted by the same mosquitoes.
• Malaria (Plasmodium falciparum) – especially severe malaria with high fever.
• Rickettsial diseases (e.g., African tick‑bite fever, Rocky Mountain spotted fever).
• Leptospirosis – bacterial infection from water contaminated with animal urine.
• Typhoid fever (Salmonella Typhi) – causes prolonged high fever.
• Viral hemorrhagic fevers (e.g., Ebola, Lassa) – share hemorrhagic features.
• Acute hepatitis A or E – can cause fever and jaundice.
• Drug‑induced fever – especially with antibiotics, antiepileptics, or immunotherapies.

Associated Symptoms

Yellow fever follows a characteristic biphasic clinical course. In the infectious phase (3–6 days), patients often experience:

• Sudden high fever
• Headache, especially behind the eyes (retro‑orbital pain)
• Severe muscle aches (myalgia) and back pain
• Chills and rigors
• Nausea, vomiting, or loss of appetite
• Generalized weakness and fatigue

About 15 % of patients progress to the toxic phase, during which additional signs appear:

• Jaundice (yellowing of skin and sclera) due to liver injury
• Dark urine and pale stools
• Abdominal pain, especially in the right upper quadrant
• Bleeding tendencies – gums, nose, gastrointestinal tract, or petechiae
• Kidney dysfunction (reduced urine output)
• Encephalopathy – confusion, seizures, or coma in severe cases

When to See a Doctor

Because yellow fever can deteriorate rapidly, seek medical care immediately if you have:

• Fever ≥ 39 °C (102 °F) that started suddenly after travel to an endemic area.
• Any sign of jaundice (yellow eyes or skin).
• Bleeding from any site (gums, nose, vomit, stool, or unexplained bruises).
• Severe abdominal pain, especially with a tender liver edge.
• Rapid worsening of mental status—confusion, lethargy, or seizures.
• Persistent vomiting that prevents you from keeping fluids down.
• Known exposure to mosquito bites in an outbreak zone without prior vaccination.

Even if symptoms are mild, a healthcare professional should evaluate all travelers returning from yellow‑fever‑risk regions, because early supportive care improves outcomes.

Diagnosis

Diagnosing yellow fever requires a combination of clinical suspicion and laboratory confirmation.

1. Clinical Assessment

• Detailed travel and vaccination history.
• Physical exam focusing on jaundice, liver size, and signs of hemorrhage.

2. Laboratory Tests

• Serology – detection of IgM antibodies against YFV (ELISA). Positive after ~5 days of illness.
• Reverse‑transcriptase polymerase chain reaction (RT‑PCR) – identifies viral RNA early (first 5 days).
• Complete blood count (CBC) – often shows lymphocytosis early, then leukopenia and thrombocytopenia.
• Liver function tests – elevated ALT/AST, bilirubin, and prolonged PT/INR.
• Coagulation profile – assesses bleeding risk.
• Renal panel – monitors creatinine and electrolytes.

3. Differential Testing

Because of overlapping symptoms, doctors will also test for malaria (rapid diagnostic test or thick smear), dengue (NS1 antigen, IgM), chikungunya, and leptospirosis to rule out other causes.

Treatment Options

There is no specific antiviral therapy for yellow fever. Management is supportive and aims to maintain organ function while the immune system clears the virus.

Hospital‑based Care (for moderate to severe disease)

• Fluid replacement – isotonic crystalloids to correct dehydration and maintain blood pressure.
• Blood products – fresh frozen plasma, platelets, or packed red cells for severe hemorrhage or anemia.
• Renal support – dialysis if acute kidney injury develops.
• Ventilatory support – for patients with respiratory failure or altered mental status.
• Antipyretics – acetaminophen (paracetamol) for fever; avoid NSAIDs that may worsen bleeding.
• Monitoring – frequent vitals, urine output, neurologic status, and laboratory trends.

Outpatient Management (mild cases)

• Rest in a cool, quiet environment.
• Oral rehydration solutions or electrolyte‑balanced drinks.
• Acetaminophen for fever and pain (max 3 g/day).
• Close follow‑up (in‑person or telemedicine) within 24–48 hours to ensure no progression.

Adjunctive Therapies

• Vitamin K – may be given if coagulopathy is significant and liver synthetic function is compromised.
• Experimental antivirals – research on favipiravir and other RNA polymerase inhibitors is ongoing, but none are approved yet.

Prevention Tips

Yellow fever is vaccine‑preventable, and prevention strategies focus on immunization and mosquito control.

Vaccination

• The 17‑D live‑attenuated yellow‑fever vaccine provides lifelong immunity for most adults.
• WHO recommends a single dose for travelers ≥ 9 months old; a booster is rarely needed, except for certain high‑risk groups (e.g., laboratory workers).
• Proof of vaccination (International Certificate of Vaccination) is required for entry into many endemic countries.

Vector Control

• Use EPA‑registered insect repellents containing DEET, picaridin, IR3535, or oil of lemon eucalyptus.
• Wear long‑sleeved shirts and long pants, especially at dawn and dusk when Aedes mosquitoes are most active.
• Sleep under insecticide‑treated bed nets if staying in areas without air‑conditioning.
• Eliminate standing water around living spaces (flower pots, tires, buckets).

Travel Precautions

• Plan vaccination at least 10 days before departure to allow seroconversion.
• Consult a travel medicine clinic for a personalized risk assessment.
• Carry a copy of your vaccination certificate and a small bottle of repellent.
• Stay informed about outbreak alerts from CDC, WHO, or local health ministries.

Emergency Warning Signs

Key Takeaways

Yellow fever remains a serious public‑health threat in tropical regions, but it is preventable with vaccination and simple mosquito‑avoidance measures. An abrupt high fever after travel to an endemic area should prompt urgent medical evaluation, especially if jaundice or bleeding appears. While there is no specific cure, supportive care in a hospital setting dramatically improves survival. If you are planning travel to at‑risk areas, ensure you are vaccinated, use repellent, and stay alert for the warning signs outlined above.

---

References:

• Mayo Clinic. “Yellow fever.” https://www.mayoclinic.org
• CDC. “Yellow Fever – Traveler Information.” https://www.cdc.gov
• World Health Organization. “Yellow fever fact sheet.” https://www.who.int
• NIH National Institute of Allergy and Infectious Diseases. “Yellow Fever.” https://www.niaid.nih.gov
• Cleveland Clinic. “Yellow Fever: Symptoms, Diagnosis, and Treatment.” https://my.clevelandclinic.org